Core Viewpoint - The healthcare sector has been the worst performing part of the market this year, yet Johnson & Johnson (J&J) stands out as a notable performer, being the 10th best performing healthcare stock in the S&P 500, with a year-to-date increase of 21.5% [1][2] Group 1: Company Performance - J&J has managed to defy the negative trends in the healthcare market, primarily due to its diversified business model that includes a significant medical device segment, which accounts for 36% of its sales [3][5] - The medical technology division has shown steady growth, particularly in cardiovascular, orthopedic, surgery, and vision areas, bolstered by major acquisitions totaling nearly $30 billion [4] Group 2: Business Segments - J&J's medtech unit is underappreciated by investors who primarily view the company as a pharmaceutical entity, despite its strong performance in medical devices [5] - The pharmaceutical segment has also been performing well, especially after the spin-off of the over-the-counter business, allowing J&J to focus on higher growth pharmaceutical products [6]